MedTrace Logo

Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C

NCT01037621 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-11-07

No results posted yet for this study

Summary

This trial is to determine the safety of valacyclovir in persons with chronic hepatitis C and herpes simplex type 2 infection. Participants will be randomized to valacyclovir or matching placebo. After receiving the initial therapy for eight weeks, the participants will cross over to the alternate therapy for an additional eight weeks. Each treatment period will be separated by a two-week period of daily placebo. The hypothesis is that treatment with valacyclovir will result in a significant reduction in serum levels of hepatitis C virus ribonucleic acid.

Conditions

  • Hepatitis C Virus Infection
  • Infection
  • Herpesvirus 2, Human

Interventions

DRUG

Valacyclovir

Valacyclovir 500 mg, 2 caplets twice daily for eight weeks

Sponsors & Collaborators

  • G.V. (Sonny) Montgomery VA Medical Center

    lead FED

Principal Investigators

  • Mary Jane Burton, M.D. · G.V. (Sonny) Montgomery VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01037621 on ClinicalTrials.gov